主页 > 医药生命 >
【技术产业】三个肺癌关联基因找到
Mutations in three genes -- TTF1, NKX2-8 and PAX9, which are linked to normal development of lungs in the embryo -- were found in 20% of non-small cell lung cancers and work together to promote tumor growth. A researcher said the findings might lead to predicting prognosis and designing individual treatment for lung cancer patients.
http://www.washingtonpost.com/wp-dyn/content/article/2007/10/09/AR2007100900858.html
今年诺贝尔生理医学奖或许能为干细胞研究推波助澜
Stem cell research advocates are hoping that the attention being given to the team that won a Nobel Prize for advances in gene manipulation might help ease the political tension over stem cell issues in the U.S. Some experts say funding shortfalls for stem cell work have hindered advances in the field, but others think a lack of scientific knowledge is the barrier to advances. ABC News
http://www.abcnews.go.com/Health/Technology/story?id=3704202&page=1
比尔盖茨夫妇基金会出钱支持健康解决方案
The Bill & Melinda Gates Foundation is trying a new approach to improve global health, launching a $100 million fund that will allow scientists working on novel ideas to access relatively small grants quickly. The move is aimed at boosting innovative approaches to health by cutting much of the bureaucracy that is often involved with traditional large grants. The Wall Street Journal 报道
金融时报分析报道: 投资生物技术创新企业继续升温
With Big Pharma showing an interest in acquiring biotech startups to boost their pipelines amid upcoming patent expirations, venture capital backers are investing heavily in the startup biotech sector. However, if prices continue to rise for early-stage, risky products, partnerships may again become the preferred route to accessing new drugs for major drugmakers, this Financial Times analysis says.
http://r.smartbrief.com/resp/iHhgnVmKfgaLjtCibGtHrMTh?format=standard
罗氏CEO对收购Ventana志在必夺
Roche chief confident of Ventana win
By Andrew Jack in London
The head of Roche has expressed renewed confidence that he will win his $3bn hostile bid for Ventana, the US diagnostic company, after claiming hedge funds have already bought out the leading shareholders.
Franz Humer, chairman and chief executive of the Swiss pharmaceutical group, told the Financial Times that he had "no intention of increasing the price" of the $75-a-share bid for Ventana he announced in June, and remained "very confident" of the success of the offer, which closes on November 1.
研究发现可以帮助治疗Huntington's 的分子
The C2-8 molecule curbs the progression of neurological damage and delays the loss of motor control in mice with Huntington's disease, a U.S. study revealed. Researchers said more study is needed but the molecule may have potential as a treatment for the neurological disorder. Yahoo!/HealthDay News [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-27 05:17
医学,生命科学网